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Abstract
A CD8+ cytotoxic T lymphocyte (CTL) line was derived from the peripheral blood mononuclear
cells of a patient with primary melanoma. The CD8+ CTL line specifically lysed the autologous
primary melanoma cells and not the natural killer cell-sensitive K562 cells or lymphokine activated
killer cell-sensitive DAUDI cells. When a large panel of human leukocyte antigen (HLA)-matched
and -unmatched allogeneic melanoma, glioma, breast and colorectal carcinoma cells was tested as
targets in cytolysis assays, 4 HLA-matched and two HLA-unmatched allogeneic metastatic
melanoma lines were lysed by the CD8+ CTL. Lysis of autologous and allogeneic melanoma cells
was dependent on the effector-to-target cell ratio. Lysis of autologous melanoma cells was not
blocked by anti-HLA class I or class II antibodies, confirming that the cytolytic activity of the CD8+
CTL was HLA-unrestricted. CTL lysis of autologous melanoma cells was CD3 (T cell receptor)
dependent and FAS-FAS-L, and CD1 independent. Identification of the melanoma-associated
antigen recognized by the HLA-unrestricted CTL may provide a vaccine for a broad population of
melanoma patients.
Background
Cytotoxic T lymphocytes (CTL) have been established
from various lymphoid sources of patients with metastatic
melanoma[1]. The majority of CTL are of CD8 phenotype
and generally lyse tumor cells in a human leukocyte anti-
gen (HLA)-restricted manner. A number of melanoma-
associated antigens and peptides defined by CD8+ CTL
have been identified and the majority of these CTL are
HLA-A2 restricted [1,2]. CD8+ CTL that recognized and
lysed melanoma targets of various HLA types also have
been described [3-6]. However, it is unclear whether the
CTL are truly HLA-unrestricted, as the allogeneic tumor
target cells used were not fully HLA subtyped [3-6] and,
therefore, partial HLA matching of these targets with the
CTL cannot be excluded with certainty. Furthermore, the
demonstration of the absence of HLA restriction was
based on the absence of CTL lysis blocking in the presence
of high concentrations of anti-HLA antibodies. However,
the high effector-to-target (E:T) cell ratios used in those
studies, accompanied by high tumor cell lysis in control
cultures [5,6] may be responsible for the absence of CTL
blocking by anti-HLA antibodies.
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We have established a CD8+ CTL line from the peripheral
blood lymphocytes of a patient with primary melanoma.
When the cytotoxic activity of the CTL line was tested
against a large panel of allogeneic cell lines of melanoma,
glioma, breast or colorectal carcinoma, autologous or all-
ogeneic Epstein-Barr virus (EBV)-transformed B cells, or
autologous fibroblasts, the autologous and a few alloge-
neic, HLA non-matched melanoma cells were lysed and
induced interferon (IFN)-γ and granulocyte monocyte-
colony stimulating factor (GM-CSF) secretion by the CTL.
Furthermore, the lysis of the autologous or allogeneic
tumor cells was not blocked by monoclonal antibodies
(MAbs) to HLA-class I or class II, confirming that the CTL
lyse targets in a HLA-unrestricted manner.
Methods
Patient 793
Patient 793 (male Caucasian, 39 years old) had excision
of a "low risk" primary melanoma [superficial spreading
type with early vertical growth phase present; the tumor
thickness was 0.55 mm and the vertical growth phase had
a brisk lymphoid infiltrate, with no evidence of metas-
tases]. The primary lesion was excised ~20 years ago and
there has been no recurrence since. The patient did not
receive adjuvant chemotherapy after removal of the pri-
mary lesion.
Cell lines
Melanoma cell line WM793 was established from the ver-
tical growth phase of a primary lesion of patient 793 [7].
Cell line 1205LU, the metastatic variant of WM793, was
established after repeated passages of WM793 cells both
in vitro and in vivo in nude mice [8]. Melanoma cell lines
WM75, WM98, WM164, and WM1158 were derived from
metastatic lesions of melanoma patients [7]. All cell lines
were maintained in McCoy's Dulbecco 153-Leibovitz 15
(MCDB153-L15) medium (Sigma, St. Louis, MO) con-
taining 2% fetal bovine serum (FBS). Metastatic
melanoma cell line DM196 was obtained from T. L. Dar-
row (Duke University Medical Center, Durham, NC) and
was maintained in Dulbecco's modified Eagle's medium
(DMEM; GIBCO-Invitrogen, Carlsbad, CA) supple-
mented with 5% FBS. Metastatic melanoma cell line
ME9874 was obtained from A. Anichini (Istituto Nazion-
ale Tumori, Milan, Italy) and maintained in RPMI 1640
Glutamax medium (GIBCO-Invitrogen) supplemented
with 10% FBS. Metastatic melanoma cell line A375 was
obtained from American Type Culture Collection (ATCC;
Rockville, MD) and maintained in RPMI 1640 medium
supplemented with 10% FBS. Rectal carcinoma cell lines
WC007 and WC008 were maintained in MCDB20l-L15
(Sigma) medium supplemented with 2% FBS[9]. The gli-
oma cell lines U373MG and U87MG (obtained from Dr.
Darell Bigner, Duke University Medical Center) and the
breast cancer cell line MDA MB231 (obtained from Dr.
Daniela Santoli, The Wistar Institute) were maintained in
DMEM medium supplemented with 10% FBS. HLA class
I and II expression by tumor cells was determined in com-
plement-dependent lysis assay using HLA typing trays
(One Lambda, Inc., Canoga Park, CA). 793 fibroblast cell
line [10] was maintained in DMEM containing 10% FBS.
EBV-transformed B cell line was established from freshly
isolated peripheral blood mononuclear cells (PBMC) of
patient 793 as described before[10]. EBV-B cell lines 888,
1363, 1088, 1102, and 4226 were established from
melanoma patients' PBMC. Natural Killer (NK) cell target
K562 (human erythroleukemia cell line) and lym-
phokine-activated killer (LAK) cell target Daudi (human
lymphoblastoid cell line) were obtained from ATCC. All
lymphoid cell lines were maintained in RPMI 1640
medium supplemented with 10% FBS.
Antibodies
The following MAbs were used: HLA-class I-specific MAb
W6/32 and HLA-class II-specific MAbs B33.1 and D1.B6
(obtained from B. Perussia, Thomas Jefferson University);
MAb H24B5 to influenza virus hemagglutinin (obtained
from W. Gerhard, The Wistar Institute); MAb ME36.1 to
GD2 and GD3; MAb ME50.8 to GD3; MAb 31.3 to chon-
droitin sulfate proteoglycan; MAb MENu4B to
v(e.c.)itronectin receptor; MAb 20.4 to nerve growth fac-
tor receptor; MAb 425 to epidermal growth factor recep-
tor; MAb 451-1-C7-1 to fibroblast marker; MAbs 439-3-
27-2-3 and 456-1-A11-2 to carbohydrates; MAbs ME7529
and ME77.1 to 120 kd protein on melanoma cells and
MAb 507-2-2-4 to uncharacterized melanoma-associated
antigen [11]. MAb HIT3a to CD3; MAb RPA-T4 to CD4;
MAb RPA-T8 to CD8; MAb M-A251 to CD25; MAb 5C3 to
CD40; MAb TRAP1 to CD40L; MAb L307.4 to B7-1
(CD80); MAb 2331 to B7-2 (CD86); MAb HI149 to
CD1a; MAb Nok-1 to CD95L (Fas ligand), and MAb DX2
to CD95 (Fas receptor) (all antibodies were obtained
from BD Pharmingen, San Diego, CA); MAb BMAO 31 to
human T-cell receptor (TCR) α/β common region (T cell
Sciences, Cambridge, MA); MAb OKT3 to CD3; MAbs 4F-
2 and 5AG to IL-4 (DNAX, Palo Alto, CA); MAbs B133.1.1
and B133.5.1 to IFN-γ; MAbs B154.9.1 and B154.9.2 to
tumor necrosis factor (TNF-α) (obtained from G. Trinch-
ieri, The Wistar Institute); and MAb C9.1 and C16.3 to
granulocyte macrophage-colony stimulation factor (GM-
CSF) [12].
Generation of anti-melanoma CTL line
CTL were obtained from co-cultures of PBMC (105 cells/
well of 96-well round-bottom microtiter plates) of
melanoma patient 793 with irradiated (40,000 rads, Cs
source) autologous melanoma cells WM793 (105 cells/
well) in RPMI 1640 medium containing 10% human AB
serum (Sigma), 10 mm HEPES (Sigma), L-arginine (116Journal of Translational Medicine 2005, 3:41 http://www.translational-medicine.com/content/3/1/41
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mg/l; GIBCO-Invitrogen), L-asparagine (36 mg/l; GIBCO-
Invitrogen), L-glutamine (216 mg/l; Invitrogen), and 2-
mercaptoethanol (ME) (5 × 10-5 M; Sigma). Cultures were
periodically stimulated with irradiated autologous tumor
cells and irradiated autologous PBMC (days 8 and 14) or
autologous EBV-B cells (from day 21 on) in RPMI 1640
medium containing partially purified IL-2 (day 3 on; 20
U/ml; Advanced Biotechnologies., Columbia, MD).
Cytotoxicity assay
This assay was performed as described previously
[9,10,13]. Briefly, labeled targets [2 µCi of 51Cr (sodium
chromate, specific activity 400–1200 Ci/g; NEN DuPont,
Boston, MA) per 1 × 104 cells] were mixed in 96-well U-
bottom microtiter plates with effector cells at various E:T
ratios and incubated at 37°C for 4 hr. Supernatants were
harvested and tested for 51Cr release (experimental
release). For maximal release, target cells were treated with
0.3% Triton X-100 (Sigma). Spontaneous release of radi-
oactivity by target cells was determined in the absence of
effector cells. Spontaneous release of the various targets
used was 10–15%. The percentage of cytotoxicity was
determined by the following formula:
The targets (WC008, U373MG and U87MG) that exhib-
ited high spontaneous 51Cr release were stained with neu-
tral red dye and used in a modified cytotoxicity assay[10].
Blocking of cytotoxic activity
Cytotoxicity blocking assays were performed as described
before [10,13]. Briefly, tumor targets were incubated with
10 µg/ml of anti-HLA-class I MAb W6/32 (IgG2a) or anti-
HLA-class II MAb B33.1 and D1.B6 (IgG2a), MAb DX2
(IgG1) to Fas or HI149 (IgG1) to CD1, and CTL were incu-
bated with 10 µg/ml of anti-CD3 MAb OKT3 (IgG2a). Iso-
type-matched control MAb H24B5 (IgG2a) or normal
mouse IgG (predominantly IgG1) were used at 10 µg/ml.
All incubations were performed for 1 hr at room temper-
ature. Following blocking of tumor cells or CTL, cytotox-
icity assays were performed as described above.
Cytokine determinations
Cultured CTL were washed twice with serum-containing
RPMI 1640 medium, incubated in serum-containing
medium (without stimulants or IL-2) for 10–12 hr at
37°C in a 5% CO2 incubator and washed once. CTL (104
cells/well) were stimulated with irradiated autologous or
allogeneic tumor or normal cells (104–105 cells/well) in
96-well microtiter plates. Supernatants obtained from cul-
tured CTL after 24 hr or 72 hr were tested for the presence
of GM-CSF, TNF-α, IL-4, and IFN-γ.
IL-4, IFN-γ, TNF-α, and GM-CSF were measured by radio-
immunoassay (RIA) as described before. [9] T cell super-
natants at various dilutions were placed in antibody-
coated wells (MAb 4F-2 to IL-4; MAb B133.1.1 to IFN-γ;
MAb B154.9.2 to TNF-α; MAb C9.1 to GM-CSF), and
binding was determined using 125I-labeled MAb specific
for different determinants on the cytokines (MAb 5AG to
IL-4; MAb B133.5.1 to IFN-γ; MAb B154.9.1 to TNF-α;
MAb C16.3 to GM-CSF). Concentrations of IL-4, IFN-γ,
TNF-α, and GM-CSF were determined using respective
recombinant cytokine standard preparations (R&D Sys-
tems Inc., Minneapolis, MN).
IL-2 expression by the T cells was tested by reverse tran-
scriptase-polymerase chain reaction (RT-PCR) as
described[10].
Phenotyping of melanoma and T cells
Cultured cells were incubated with saturating concentra-
tions (5 µg/ml) of either unlabeled or fluoresceinated or
phycoerythrin(PE)-labeled MAbs detecting human lym-
phocyte markers (CD3, CD4, CD8, CD25, CD40, CD40L,
CD80, CD86, CD95, and CD95L) or melanoma-associ-
ated antigens (ME36.1, ME50.8, 31.3, MENu4B, 20.4,
425, 451-1-C7-1, 439-3-27-2-3, 456-1-A11-2, ME7529,
77.1 and 507-2-2-4) in RPMI 1640 medium supple-
mented with 5% human AB serum for 45 min at 4°C.
Cells were washed 3× and stained with fluorescein isothi-
ocyanate conjugated (FITC) second antibody [goat anti-
mouse F(ab)2, 1:200 dilution, ICN-Cappel, Irvine, CA].
Binding of the PE or FITC-conjugated antibodies was ana-
lyzed in the cytofluorograph (Ortho Diagnostics, Rariton,
NJ). All values given in "Results" are corrected for irrele-
vant, isotype-matched control antibody binding.
TCR analysis by RT-PCR
TCR was analyzed as describted previously[10]. In brief,
mRNA was extracted from 3 × 106 T cells using the mRNA
DIRECT kit (Dynal Biotech, Lake Success, NY). RT-PCR
and cDNA synthesis were performed using the SuperScript
One-Step RT-PCR kit (Invitrogen, Carlsbad, CA), specific
5' primers encoding variable Vα (1–22) and Vβ (1–24)
and a common C region (Cα and Cβ) 3' primer. PCR
products were run on 2% agarose gels and analyzed.
Statistical analyses
Differences between experimental and control values
(triplicates or quadruplicates) were analyzed for signifi-
cance by Student's two-sided paired t-test.
Results
Phenotypic characteristics of T cell line
A T cell line was generated in mixed lymphocyte/tumor
culture (MLTC) by stimulating the PBMC of melanoma
patient 793 with irradiated autologous WM793
% cytotoxicity =
experimental release - spontaneous release
m maximal release - spontaneous release
×100Journal of Translational Medicine 2005, 3:41 http://www.translational-medicine.com/content/3/1/41
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melanoma cells. Cultures received IL-2 from day 3 on and
were restimulated with irradiated autologous tumor cells
and IL-2 every week. The T cell line was >98% CD8+ (Table
I). The CD8+ T cell line expressed HLA class I and II, CD3,
CD25, FAS, FASL, B7-1, and B7-2, and a low percentage of
the cells also expressed CD40 and CD40L (Table I). The T
cell line expressed TCR α/β chains. Further, RT-PCR anal-
ysis indicated that the T cell line is oligoclonal as it
expresses Vα2, Vα4, Vα14, Vα16 and Vβ6 chains.
Attempts to clone CD8+ T cell line by limiting dilution
were unsuccessful twice. WM793 melanoma cells
expressed HLA class I and II and FAS, and a low percentage
of the cells expressed FASL, B7-1, and B7-2 (Table I).
Cytolytic activity of CD8+ CTL line against various HLA-
matched and non-matched tumor and non-tumor cells
The cytolytic activity of the CD8+ CTL line against autolo-
gous and allogeneic partially HLA-matched and
unmatched melanoma cells was tested at various E:T
ratios (6.25–50) at 8 weeks in culture. As controls, NK sus-
ceptible target (K562) and LAK sensitive target (Daudi)
were used. The CTL line lysed autologous WM793
melanoma cells as well as partially HLA-matched
(DM196, ME9874, A375 and WM75) and HLA-
unmatched allogeneic melanoma cells (WM164 and
WM1158), but not NK-sensitive K562 or LAK-sensitive
Daudi cells (Fig. 1). In contrast to autlogous WM793
melanoma cells, which were non-metastatic in nude mice
and lysed by CTL 793, 1205LU metastatic variant cells of
WM793 cells isolated from nude mice were not lysed by
the CTL (Table II). Absence of 1205LU lysis by CTL793
cannot be explained by absence of the expression of
known melanoma-associated antigens or HLA class I in
1205LU cells, compared to WM793 cells (Fig. 2). How-
ever, we cannot exclude the possibility that other antigens
are differentially expressed by the two melanoma cell
lines. Thus, the antigen recognized by the CTL may be
expressed by primary (WM793), but not metastatic vari-
ant (1205LU) melanoma cells, derived from the same
patient. However, expression of HLA class II was low
(<5%) in 1205LU cells compared to WM793 cells (Fig. 2).
Since CTL793 are CD8+, we do not expect HLA class II to
play a role in WM793 lysis by the CTL. Furthermore, there
is strong evidence that CTL793 are HLA unrestricted in
their capacity to lyse autologous tumor cells (see below).
A larger panel of allogeneic HLA-matched and -
unmatched melanoma, glioma, breast and colorectal car-
cinoma cells were used as targets in cytotoxicity assays. Of
the eight allogeneic melanoma cells used as targets in CTL
assays, six (DM196, ME9874, A375, WM75, WM164, and
WM1158) were significantly (at p < 0.05 level) and con-
sistently (in 2 different assays) lysed (Fig. 1, Table II). Four
of the six allogeneic melanoma cell lines that were lysed
by the CTL share HLA-A1, A29 and/or B57 [17] alleles
with the autologous WM793 cells. Two of the cell lines
(WM164 and WM1158) lysed by the CTL (Fig. 1, Table II)
were HLA-unmatched. There was no significant lysis of
allogeneic partially HLA-matched melanocytes (FOM708,
FOM723, FOM1020), autologous 793 EBV-B cells, alloge-
neic HLA-unmatched glioma cells (U87MG and
U373MG), breast carcinoma (MDAMB231) or colorectal
carcinoma (WC007 and WC008) cells (Table II).
Cytokine secretion of CD8+ CTL793
Supernatant from CD8+ CTL793 after 24–48 hr of stimu-
lation with autologous melanoma cells WM793 con-
tained significant amounts of IFN-γ, TNF-α, and GM-CSF,
but not IL-2 or IL-4 (data not shown, except for IFN-γ
release in Table II). IFN-γ, TNF-α, and GM-CSF were pro-
duced by the CTL, and not by irradiated autologous
melanoma cells, since the supernatants derived from the
melanoma cells showed no significant cytokine secretion
(data not shown). To determine the specificity of cytokine
release by the CTL, IFN-γ and GM-CSF production by the
CTL after stimulation with various tumor and non-tumor
cells was determined (Table II). All six allogeneic, partially
HLA-matched melanoma cells, (DM196, ME9874, A375,
WM75, WM164 and WM1158) induced significant IFN-γ
and GM-CSF production by the CTL and also were lysed
by the CTL (Table II). None of the cell lines derived from
gliomas, breast and colorectal carcinomas, or melano-
cytes, fibroblasts or EBV-B lymphocytes induced IFN-γ
release by the CTL (Table II).
Table 1: Phenotypic markers of CD8+ CTL793 and WM793 
Melanoma Cells
Percent cells positive
Parameter investigated CD8+ CTL793 WM793 melanoma cells
HLA Class I 95 97
HLA Class II 95 74
CD1 NAa 18
CD3 90 NA
CD4 0 NA
CD8 98 NA
CD25 80 0
CD95 (FAS) 98 95
CD95L (FAS-L) 89 10
CD80 (B7-1) 88 7
CD86 (B7-2) 32 3
CD40 10 3
CD40L 18 6
TCRα/β 92 NA
a NA = not applicable.Journal of Translational Medicine 2005, 3:41 http://www.translational-medicine.com/content/3/1/41
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Table 2: Lysis of various HLA-matched and -unmatched target cells and IFN-γ secretion by CD8+ 793CTL
Stimulator and target cell HLA subtypea % Maximal IFN-γ secretion GM-CSF secretion
Designation Origin Cyto-toxicityb (U/ml)c (U/ml)
WM793 Autologous primary melanoma A1, A29, B57[17], B35, DRB1 11, 
DQB1 0301
40.1d 10d 5.1d
1205LUe Autologous metastatic variant A1, A29, B57[17], B35, DRB1 11, 
DQB1 0301
6.6 <0.01 <0.01
DM196 Allogeneic metastatic melanoma A23(9), Aw34, B57[17], B44, DR1, DR3, 
DRw1, DRw52
12d 2.2d 2.5d
ME9874 Allogeneic metastatic melanoma A2, A24, B57[17], B60, Cw3, Cw7, 
DR7, DQ2
8.3d 5.9d 3.2d
A375 Allogeneic metastatic melanoma A1, A2, B57[17], C6 20.3d 41.2d 6.2d
WM75 Allogeneic metastatic melanoma A2, A29, B12w44, DR4, DR7 24.2d 4.6d 2.0d
WM98 Allogeneic metastatic melanoma A1, A3, B8, DR3 8.1 <0.01 <0.01
WM164 Allogeneic metastatic melanoma A24, B7, C7, DR13, DQ1, DQ6, DRw52 29.8d 1.6 2.0d
WM1158 Allogeneic metastatic melanoma A11, A24, B16, B60 (40), C3, DR13, DR4, 
DQ3, DQ6, DRw52, DRw53
45d <0.01 <0.01
U87MG Allogeneic glioma A2, B7, B44, Cw05, Cw07, DRB1 03, 
DRB115, DQB1 02, DQB1 06
0 <0.01 N.D.
U373MG Allogeneic glioma A2, B18, Cw05, DRB103 0 <0.01 N.D.
MDAMB231 Allogeneic breast carcinoma A2, B40, B41, Cw02, Cw17, DRB1 07, 
DRB1 13, DQB1 02, DQB1 03
0 <0.01 N.D.
WC007 Allogeneic colorectal carcinoma A1, A3, B35, DR1, DR4 0 <0.01 N.D.
WC008 Allogeneic colorectal carcinoma A1, A3, B15,B57[17], DR4 0 <0.01 N.D.
FOM708 Allogeneic melanocytes A1, A11, B7, B8, C1, C6 3.7 <0.01 <0.01
FOM723 Allogeneic melanocytes A3, A29, B7, B44 7.8 <0.01 <0.01
FOM1020 Allogeneic melanocytes A2, A3, B37, B57, C6 5.2 <0.01 <0.01
793 
fibroblasts
Autologous fibroblasts A1, A29, B57[17], B35, DRB1 11, 
DQB1 0301
N.D.f <0.01 N.D.
793 EBV-B Autologous B cells A1, A29, B57[17], B35, DRB1 11, 
DQB1 0301
0 1.3 N.D.
888EBV-B Allogeneic B cells A1, A24, B52, B55, C1, C7, DR15 N.D. <0.01 N.D.
1363EBV-B Allogeneic B cells A1, A2, B44, B51, C1, DR1 N.D. <0.01 N.D.
1088EBV-B Allogeneic B cells A1, A2, B8, B44, C5, DR4, DR17 N.D. <0.01 N.D.
1102EBV-B Allogeneic B cells A2, A24, B55, B62, C3, DR4, DR15 N.D. <0.01 N.D.
4226EBV-B Allogeneic B cells A24, A32, B27, B38, C3, DR4, DR15 N.D. <0.01 N.D.
K562 NK-sensitive erythroleukemia 
cells
N.D. 0 <0.01 N.D.
Daudi lymphokine-activated killer cell-
sensitive lymphoma cells
N.D. 0 <0.01 N.D.
a Based on tumor cell typing, except for WM75 and WM98 (based on lymphocyte typing). HLA types of WM793 cells and those matching between 
WM793 and other cells are in bold.
b Lysis of labeled tumor target cells was determined in 4-hr 51Cr release assay using optimal E:T ratio of 20. Values represent means of triplicate 
determinations. Each cell line was tested in at least 2 different assays with similar results.
c IFN-γ and GM-CSF secretions were determined by RIA. Values represent means of triplicate determinations. Each cell line was tested in at least 2 
different assays with similar results.
d p < 0.05 when compared to corresponding cpm values of spontaneous release of 51Cr by target cells and/or spontaneous release of cytokine by 
CTL.
e Lung metastasis obtained in nude mice by injecting autologous WM793 cells s.c.[8]
f N.D. = Not determined.
Blocking of CTL activity of CD8+ CTL793 using various 
MAb
Melanoma cells WM793 express HLA-class I and II (97%
and 74% of the cells positive, respectively; Table I). CTL
activity against autologous WM793 cells was not blocked
by pre-incubating target cells with saturating concentra-
tions of MAb to HLA-class I (W6/32) or class II (MAb
B33.1 or MAb D1.B6) (Table III), indicating that CTL
activity is HLA-unrestricted. Surprisingly, these MAbs
enhanced tumor cell lysis (Table III). In our related stud-
ies, these MAbs were able to block the tumor target cell
lysis of other HLA-restricted CTLs [10,13]. CTL activity
against partially matched allogeneic DM196 melanoma
cells was not blocked by MAb to HLA class I (data not
shown), indicating that CTL activity is HLA unrestricted.Journal of Translational Medicine 2005, 3:41 http://www.translational-medicine.com/content/3/1/41
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CTL793 express FAS-L and WM793 melanoma cells
express FAS (Table I). To determine the role of FAS and
FAS-L interaction in 793 CTL-mediated lysis of WM793
tumor targets, tumor cells were incubated with anti-FAS
MAb DX2 before the CTL activity against the cells was
tested. Anti-FAS MAb was unable to block 793 CTL lysis of
WM793 target cells (Table III), indicating that CTL killing
is independent of the FAS and FAS-L mediated pathway.
Low percentage of WM793 cells expresses CD1 (Table I).
The role of CD1 in CTL793-mediated lysis of WM793
tumor targets was tested by incubating tumor cells with
anti-CD1 MAb HI149 before the CTL activity against the
cell was tested. Anti-CD1 MAb was unable to block 793
CTL lysis of WM793 target cells, indicating that CD1 is not
involved in CTL-mediated lysis of tumor cells (Table III).
CTL activity of 793 CTL against WM793 cells was signifi-
cantly blocked by preincubating effector cells with saturat-
ing concentrations of anti-CD3 MAb (Table III). Thus,
lysis of target cells is mediated by TCR.
Discussion
There are a number of reports of HLA-unrestricted CD8+
CTL derived from the lymphocytes of melanoma patients
[3-6,14]. Kubo et al [14] described two CTL clones, each
expressing a single TCR (αβ) and recognizing HLA-
matched tumor targets in an HLA-restricted fashion and
HLA-unmatched targets in an HLA-unrestricted manner.
HLA-unrestricted CTL from ovarian, breast and pancreatic
carcinoma patients also have been reported and they are
known to recognize epitopes of mucin (MUC1) tumor-
associated antigen [15-17]. However, it is unclear whether
the CTL against melanomas and carcinomas are truly
HLA-unrestricted, as target cells were not fully HLA sub-
typed [3-6] and high E:T cell ratios were used in cytolysis
assays [5,6] (see Introduction).
Our study provides strong evidence that the cytolytic
activity of the CD8+ 793 CTL line is HLA-unrestricted. We
have tested our CTL in two sets of experiments to confirm
that the cytolytic activity is HLA-unrestricted. In the first
set of experiments we have used a panel of HLA-matched
and -unmatched melanoma targets in CTL lysis assays
(Table II). The target cells were fully HLA subtyped. In the
second set of experiments we have used anti-HLA anti-
bodies to block the cytolytic activity of the CTL at low E:T
cell ratios (Table III). CD8+ 793 CTL line lysed autologous
melanoma cells, and four different partially HLA-matched
(HLA-A1, A29 or HLA-B57 [17] alleles) and two
unmatched allogeneic melanoma cells; none of the allo-
geneic tumor cell lines derived from glioma, breast or
colon carcinoma were lysed. These results suggest that the
CD8+ CTL lysed melanoma targets in an HLA-unrestricted
manner. These results were confirmed in cytokine release
assays and in assays where autologous tumor cells were
incubated with MAb to HLA-class I or -class II prior to
determining tumor cell lysis by the CTL at low E:T ratios.
Unexpectedly, pre-incubation of tumor cells with MAb to
HLA-class I or -class II resulted in enhancement of CTL
tumor lysis (Table III). Similar enhancement of CTL target
cell lysis in the presence of anti-HLA antibodies was
observed by other investigators [3,4], although the mech-
anism of this phenomenon is unknown.
Our data rule out a role of Fas/Fas ligand interaction in
tumor cell lysis by the CD8+ CTL line as MAb to FAS was
unable to block CTL lysis of melanoma cells in spite of
expression of FAS-L and FAS by the CTL and tumor cells,
respectively (Table I).
Table 3: Absence of Cytotoxicity blocking of CD8+ 793 CTL line against WM793 by MAbs
MAba % WM793 target cell lysis % Inhibition of WM793 
target cell lysisb
Designation Specificity Isotype
W6/32 HLA class I IgG2a 27.9 -47.6
B33.1 HLA class II IgG2a 23.8 -26.0
D1.B6 HLA class II IgG1 21.0 -11.3
DX2 FAS (CD95) IgG1 19.9 -5.3
OKT3 CD3 IgG2a 5.2 72.5c
HI149 CD1 IgG1 23.6 -28.9
H24B5d Influenza virus IgG2a 18.9 2.6
Normal mouse Igd Unknown Predominantly IgG1 18.3 3.2
a Tumor targets were incubated with MAb (saturating concentrations, 10 µg/ml) for 1 hr at room temperature and excess MAb was removed 
before the 4-hr 51Cr-release assay.
b Negative values indicate enhancement of lysis. Means of triplicate determinations at E:T ratios of 2.
c Value significantly (p < 0.01) different when compared to isotype matched control antibody.
d Isotype-matched control antibodies.Journal of Translational Medicine 2005, 3:41 http://www.translational-medicine.com/content/3/1/41
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Cytotoxic reactivity of CD8+ CTL line against autologous melanoma cells Figure 1
Cytotoxic reactivity of CD8+ CTL line against autologous melanoma cells. CD8+ CTL line was generated in MLTC 
by stimulating the PBMC of melanoma patient 793 with irradiated autologous WM793 melanoma cells. Cultures received IL-2 
from day 3 onward, and were restimulated every 7 days for 2 months with autologous irradiated melanoma and EBV-B cells or 
PBMC. Cytotoxic effector cell responses were measured after 8 weeks. CTL lysis of 51Cr-labeled: A) autologous WM793 
melanoma cells (❍ ); B) allogeneic partially HLA-matched DM196 (), ME9874 (∆), A375 (Ќ), and WM75 () melanoma cells; 
C) HLA-unmatched allogeneic melanomas WM164 (■ ) and WM1158 (● ); D) NK cell target K562 (▲ ) lymphokine-activated 
killer cell target Daudi (◆ ) was determined in 4 h 51Cr-release assays using E:T ratios of 6.25–50.
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The CD8+ CTL described here recognize an antigen(s)
preferentially expressed by melanoma cells. This antigen
was not present on allogeneic cell lines of glioma (two),
breast carcinoma (one), and colorectal carcinoma (two),
or allogeneic partially matched melanocytes (three) or
autologous fibroblasts (one), and autologous (one) or all-
ogeneic (five) EBV-B cells. A presumably HLA-unrestricted
CTL clone recognizing a determinant shared by allogeneic
melanoma and lung carcinoma cells has been described
[14]. A short-term presumably HLA-unrestricted CTL line
established by repeated stimulation of lymph node T cells
obtained from a pancreatic carcinoma patient recognized
and lysed MUC-1 positive pancreatic, breast, and ovarian
carcinoma cells[15,17]. To our knowledge, MUC-1 is not
expressed by melanoma cells, and thus it is highly
unlikely that MUC-1 is the candidate antigen responsible
for CD8+ CTL-mediated lysis.
Identification of the melanoma-associated antigen recog-
nized by the CD8+, HLA-unrestricted CTL described here
will provide a vaccine for a broader population of
melanoma patients. The antigen is expressed by the
majority of allogeneic, metastatic melanoma cells,
although it is lost by metastatic variant cells isolated from
primary, autologous WM793 melanoma cells by passag-
ing these cells in nude mice.
List of abbreviations
CTL, cytotoxic T cell; EBV, Epstein-Barr virus; E:T, effector-
to-target; FITC, fluorescein isothiocyanate; GM-CSF, gran-
ulocyte monocyte-colony stimulating factor; HLA, human
leukocyte antigen; IFN-γ, interferon gamma; IL, inter-
leukin; LAK, lymphokine-actived killer; MAb, mono-
clonal antibody; MLTC, mixed lymphocyte tumor culture;
MUC1, mammary/pancreas mucin; PBMC, peripheral
blood mononuclear cells; PE, phycoerythrin; RIA, radio-
immunoassay; RT-PCR, reverse transcriptase-polymerase
chain reaction; TCR, T-cell receptor; TNF, tumor necrosis
factor.
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